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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
nebulized hypertonic saline solution reduces hospital admission rates when compared to
nebulized normal saline solution in children less than or equal to 24 months of age diagnosed
with acute bronchiolitis in the emergency department setting.
STUDY DESIGN: Systematic review of three randomized, double-blind, placebo controlled
trials in the English language all published in 2014.
DATA SOURCES: Data sources obtained for this review were articles published in peerreviewed journals found using PubMed Database.
OUTCOMES MEASURED: The outcome measured was hospital admission rate. Hospital
admission rate is calculated as the number of patients requiring inpatient hospitalization divided
by the total number of patients randomized.
RESULTS: Three double-blind randomized, controlled trials were included and analyzed in this
review. The study by Wu et al showed a statistically significant reduction (p=0.01) in hospital
admission rate with the administration of nebulized hypertonic saline compared to nebulized
normal saline with a number needed to treat (NNT) of 9. The second study by Jacobs et al
showed a decrease in admission rate with hypertonic saline that was not statistically significant
compared to control. The third study by Florin et al showed a slight increase in hospital
admission rate with the use of nebulized hypertonic saline compared to control that was not
statistically significant.
CONCLUSIONS: The results of the randomized, controlled trials were conflicting. Future study
is warranted to evaluate the efficacy of hypertonic saline in reducing hospital admission rate.
KEY WORDS: Bronchiolitis; nebulized hypertonic saline; admission rate
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INTRODUCTION
Bronchiolitis is a common viral infection of the lower respiratory tract that is responsible
for substantial morbidity in children under two years of age. It is the most common cause of
hospitalization and acute illness in children under one years old,1 with over 100,000 hospital
admissions annually in the United States.2 Total inpatient healthcare costs exceed $1.7 billion
dollars annually.3 Epidemiologic data suggests that respiratory syncytial virus, or RSV, is
responsible for approximately 65% of hospitalizations due to bronchiolitis.4 Other viral culprits
of bronchiolitis include, but are not limited to, rhinovirus, human bocavirus, human
metapneumovirus, adenovirus, coronavirus, and influenza.5 Bronchiolitis is generally seasonal,
with the majority of cases occurring in the winter months. However, patients who are
immunosuppressed may be vulnerable to RSV infection throughout the year. RSV infection does
not award lifelong immunity, and reinfection throughout life is common. Because this disease
process is so prevalent in pediatrics, and is a common cause for significant respiratory distress in
infants, primary care providers and emergency department clinicians alike need to be well versed
in treatment modalities for acute bronchiolitis.
Bronchiolitis first begins in the upper respiratory tract and then spreads distally to the
lower respiratory tract within a few days. Subsequent inflammation in the bronchioles follows
due to both the infiltration of mononuclear cells and edema of the submucosa. Consequently,
necrotic epithelial tissue and fibrin occlude the airway to varying degrees. As the cellular debris
is cleared from the airway via coughing or immune response mechanisms, the patient’s clinical
picture can rapidly change and result in an inaccurate diagnosis or an underappreciated severity
of the illness. Air trapping distal to the site of obstruction can create atelectasis and a mismatch
of ventilation and perfusion that may lead to hypoxemia, particularly in infants who have poorly
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developed collateral ventilation pathways. Receiving high flow supplemental oxygen can
exacerbate atelectasis due to its proclivity to rapid absorption compared to room air. Smoothmuscle constriction plays very little role in the pathogenesis of bronchiolitis, which explains the
limited benefit of bronchodilator therapy in treating this disease.6
Initially, signs and symptoms of bronchiolitis are similar to the common cold. These
include cough, fever, rhinorrhea, nasal congestion, fatigue, and irritability. Later on in its course,
the cough worsens and wheezing and rales can develop. More serious signs and symptoms
include poor feeding, dehydration, tachypnea, increased work of breathing, and even cyanosis.
Importantly, bronchiolitis is a clinical diagnosis. The American Academy of Pediatrics
has stated that evidence-based reviews have not shown support for the role of any diagnostic
testing in managing routine bronchiolitis.2 With that being said, chest radiographs may show
hyperinflation of the lungs indicative of air trapping, as well as atelectasis1. Rapid viral antigen
testing is another tool in the diagnostic arsenal, but because most viral infections have similar
courses in bronchiolitis, viral testing adds little to its management.
The treatment of bronchiolitis has been heavily studied and continues to be an area of
active research. The American Academy of Pediatrics (AAP) recently revised its 2006 clinical
practice guideline with respect to the management of acute bronchiolitis in 2014.2 The AAP
advocates against the use of bronchodilators with and without epinephrine to infants and children
with a diagnosis of bronchiolitis. The AAP also recommends against systemic corticosteroid use,
chest physiotherapy, and antibacterial medications unless secondary bacterial infection is
suspected. Interestingly, the AAP suggests the use of nebulized hypertonic saline to infants and
children hospitalized with bronchiolitis, but not to patients in the emergency department setting.2
Research has shown that nebulized hypertonic saline can increase mucociliary clearance by
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decreasing the viscosity of mucus secretions and airway edema as the hypertonicity of the
solution generates water absorption from the bronchiole submucosa.6 Similarly, inhaled
hypertonic saline has long been an accepted treatment in cystic fibrosis patients by acutely
improving mucociliary clearance. Although the pathophysiology of cystic fibrosis and
bronchiolitis are much different, the disease processes are similar in that both involve mucus
plugging and slowed mucociliary clearance.
The efficacy regarding the use of nebulized hypertonic to decrease hospital admission
rates from an emergency department setting is conflicting and remains unclear.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not nebulized
hypertonic saline solution reduces hospital admission rates when compared to nebulized normal
saline solution in children less than or equal to 24 months of age diagnosed with acute
bronchiolitis in the emergency department setting.
METHODS
The studies that were selected during the construction of this EBM review were three
randomized, double-blind, placebo controlled trials.7, 8, 9 The population studied in the trials
included children with the diagnosis of acute bronchiolitis in the emergency department from
ages 6 weeks to 24 months of age. The interventions in each study involved administration of
nebulized hypertonic saline solution; Wu et al and Florin et al used 3% saline whereas Jacobs et
al used 7% saline. For reference, normal saline solution is 0.9% sodium chloride. The outcome
measured that is of particular interest to this EBM review was hospital admission rate.
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Using PubMed and Cochrane databases, I researched the three selected studies.
Keywords used in the literature search were “nebulized hypertonic saline”, “bronchiolitis”, and
“admission rate”. All articles were published in English in peer-reviewed journals and were
selected based on significance and application, as well as the condition that outcomes measured
were patient oriented outcomes (POEMS). Inclusion and exclusion criteria were similar across
all three articles. Inclusion criteria involved children less than 24 months of age with a primary
diagnosis of acute bronchiolitis in the emergency department. Exclusion criteria were patients
over 24 months of age, patients with pre-existing heart, lung, or kidney disease, patients born at
less than 34 weeks gestational age, patients with a history of asthma, and those in which
informed consent could not be obtained. Table 1 demonstrates the demographics of the studies
included in this EBM review. The statistics used were relative risk reduction (RRR), absolute
risk reduction (ARR), number needed to treat (NNT), and p-values.
Table 1: Demographics & Characteristics of included studies
Study

Type

#Pts

Age

Inclusion
Criteria

Exclusion
Criteria
Patients with a
history of
wheezing or
bronchodilator use,
gestational age <34
weeks, or those
with congenital
heart disease, lung
disease, or
tracheostomy.
Patients with a
history of
wheezing,
bronchodilator use
within 2 hours of
presentation,
gestational age <34
weeks, history of
congenital heart
disease, chronic
pulmonary disease,

Wu7
(2014)

Double
blind
RCT

408

< 24
months

Pts < 24 months
with a primary
diagnosis of
bronchiolitis
during
bronchiolitis
season
(NovemberApril).

Jacobs8
(2014)

Double
blind
RCT

101

6 weeks to
< 18
months

Patients age 6
weeks to <18
months
presenting to the
ED from
October-March
from 2010-2012
with a diagnosis
of bronchiolitis.

W/D

Interventions

24

4mL of 3%
nebulized
hypertonic
saline

0

0.5mL 2.25%
racemic
epinephrine
mixed with
3mL of 7%
hypertonic
saline

ALECXIH, HYPERTONIC SALINE & BRONCHIOLITIS 5

Florin9
(2014)

Double
blind
RCT

62

2 months
to < 24
months

Patients aged 2
months to <24
months
presenting to the
ED with a first
episode of acute
bronchiolitis,
defined as their
first episode of
wheezing with
signs and
symptoms of
respiratory
distress and
upper respiratory
infection.

chronic renal
disease, O2 sat of
<85% at time of
recruitment, severe
disease requiring
ICU admission, or
inability to obtain
informed consent.
Infants with history
of wheezing or
asthma, history of
bronchodilator
therapy, chronic
lung or heart
disease, critical
illness, and
inability to receive
nebulized
medication. Infants
with non–Englishspeaking guardians
were excluded
because of inability
to provide fully
informed consent
within the study
time constraints.

0

4mL of 3%
nebulized
hypertonic
saline

OUTCOMES MEASURED
Outcomes measured were those of patient-oriented evidence that matters (POEMS). Each
article measured the hospital admission rate when nebulized hypertonic saline solution was
administered, compared to that of administered nebulized normal saline solution in the
emergency department setting. Admission rate was calculated as the number of patients requiring
inpatient hospitalization divided by the total number of patients randomized.
RESULTS
Three randomized, controlled trials were analyzed in this review. Each study compared
nebulized hypertonic saline solution to nebulized normal saline solution in children less than or
equal to 24 months of age with acute bronchiolitis in emergency department settings. Children
with a history of wheezing or asthma, chronic heart or lung disease, severe disease, gestational
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age less than or equal to 34 weeks, bronchodilator use prior to arrival, or those with inability to
obtain informed consent were excluded from the studies.7, 8, 9
The study by Wu et al7 recruited 408 patients from the emergency department from
March 1st, 2008 through April 30th, 2011. These patients were recruited from two freestanding
urban children’s hospitals in California. Seven patients from each study group left or were
transferred before receiving treatments, seven patients were withdrawn due to parent request, and
three patients were withdrawn due to a change in diagnosis. Patients received 2.5mg of nebulized
albuterol sulfate followed by 4mL of either nebulized hypertonic of normal saline. In the group
that received nebulized normal saline, 84 patients out of 192 patients (43.8%) required admission
compared to the 61 patients out of 192 (31.8%) in the group that received the nebulized
hypertonic saline solution. The difference in admission rate between the two groups remained
statistically significant (p = 0.01) after adjusting for sociodemographic clinical predictors such as
male sex, patient weight, baseline respiratory rate, and baseline oxygen saturation. The absolute
risk reduction (ARR) was 12%, and thus patients with bronchiolitis had a 12% absolute lower
risk of being admitted to inpatient care with nebulized hypertonic saline compared to control.
The number needed to treat (NNT) to prevent 1 hospitalization was 8 patients.
The study by Jacobs et al8 recruited 101 patients from an emergency room in an urban
tertiary care center between October 2010 and March 2013. This study was different from the
other two studies in the fact that the intervention studied had a much higher tonicity (7%) than
the 3% saline solution the other two studies chose to analyze. In this study, 22 out of 52 patients
(42%) in the intervention group were admitted to inpatient care compared to 24 out of 49 patients
(49%) in the normal saline control group. The number needed to treat to prevent 1 hospitalization
was 15 patients. The statistical significance (at the 0.05 significance level) was reported as an
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odds ratio with a 95% confidence interval as a proportion of the p-value. This study found that
the difference in the proportion of patients admitted in each group was not statistically significant
as the confidence interval contains 1.0.
The third study by Florin et al9 recruited 62 patients from a tertiary care emergency
department from November 1st, 2010 to April 30th, 2011. This randomized controlled trial
administered either nebulized hypertonic saline or normal saline within 90 minutes after a trial of
nebulized albuterol and nasal suctioning. There were 22 out of 31 patients (71%) admitted in the
hypertonic saline group compared to 20 of 31 patients (65%) admitted in the normal saline
group. Interestingly, the number needed to treat was -16, and thus for every 16 patients treated
with nebulized hypertonic saline, there is 1 less patient prevent from becoming hospitalized.
However, the difference in admission rate was not statistically significant with a p-value of 0.86.
Table 2 demonstrates the statistics reported in each of the studies included in this EBM
review.
Table 2: Efficacy of nebulized hypertonic saline in reducing hospital admission rate
Study

CER

EER

RRR

ARR

NNT

P value (95% CI)

Wu7

0.56

0.68

0.21

0.12

8

0.01

Jacobs8

0.51

0.58

0.14

0.07

15

OR= 0.76 (0.35-1.7)

Florin9

0.35

0.29

-0.17

-0.06

-16

0.86

DISCUSSION
The study by Wu et al claims to be the largest study evaluating the efficacy of hypertonic
saline solution in the treatment of acute bronchiolitis with 384 patients, and it found the
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intervention to significantly reduce the hospital admission rate when given in the emergency
department. The duration of action of the hypertonic saline was rapid, and most of the patients
only received one dose of the medication in this study. This individual study demonstrated
convincing evidence that nebulized hypertonic saline solution could reduce hospital admission
rate when administered in the emergency department. As discussed previously, bronchiolitis is a
major contributor to hospitalization in children, which causes significant morbidity in the
pediatric population. With that being said, this study is persuasive given the sizable study
population recruited for this specific analysis.
One of the major limitations to the Wu et al study was the fact that the majority of
patients recruited were Hispanic, and thus the generalizability of the study is quite limited. As
mentioned earlier, those with congenital heart and lung defects were excluded from the study (in
addition to all of the studies this EBM review analyzed) and, consequently, the results cannot be
applied the pediatric population with these defects.
Jacobs et al chose to look at 7% nebulized hypertonic saline solution compared to
nebulized normal saline in 101 patients. Both intervention and control were mixed with 0.5mL
2.25% racemic epinephrine and driven by 6L per minute oxygen flow. Infants with acute
bronchiolitis presenting to the emergency department had a 7% lower risk of being hospitalized
compared to control, however it was found to be statistically insignificant and drawing any
conclusions from the data reported would be inappropriate. It is important to note that this study
had less than 25% of the sample size Wu et al had studied.
There were several limitations to this study. First, admission rate, although an outcome
the study chose to compare, was actually a secondary outcome and not the primary purpose of
the study. Therefore, this randomized controlled trial was not designed nor intended for the study
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of hospital admission rate. Moreover, the study population was infants with moderate
bronchiolitis, and so the potential benefit of 7% hypertonic saline in severe bronchiolitis cannot
be excluded.
The study by Florin et al was interesting in the fact that it analyzed the effects of
hypertonic saline solution in children with persistent respiratory distress one hour after
subsequent bronchodilator therapy and nasal suctioning. With respect to admission rate, the
study found nebulized hypertonic saline solution actually worsened patient outcomes in regards
to admission rate compared to nebulized normal saline. Florin et al explained several potential
mechanisms for their findings. One rationalization is that hypertonic saline, as well as albuterol,
can transiently increase bronchial secretions and thus can induce cough. Because patients who
present to the emergency department already have intensified symptoms and disease
presentation, the hypertonic saline may have had an additive effect on the nebulized albuterol,
and caused increased symptoms and temporary respiratory distress resulting in admission.
However, the increase in admission rate was not statistically significant when compared to
control.
This study presented several limitations, one of which being the timing of drug
administration. The delivery of the albuterol and 3% hypertonic saline was intended to be such
that the patient was to be assessed as the effects of hypertonic saline peaked, but well after the
peak of albuterol. The possibility of residual effects from albuterol exists, interfering with the
effects of the hypertonic saline and thus confounding results. Secondly, the number of patients
recruited in this study was only 62, by far the smallest study population of the three trials
analyzed. Consequently, even though the intervention group had a 71% admission rate compared
to the 65% in the control group, the difference was only a matter of 2 patients. The small sample
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0
size, relative to how prevalent bronchiolitis is in this age group, may be too limited to draw
proper conclusions.
One of the largest limitations to each of the studies was the use of bronchodilator therapy.
The use of hypertonic saline is an established diagnostic test in asthmatics as a way to separate
those with the disease from those without.10 Hypertonic saline has dose dependent effects, and
can induce bronchospasm in asthmatics. The concentrations used for this diagnostic test range
from 4.5%-7%.11 However, as mentioned previously, bronchiole hyperresponsiveness is not a
pathophysiologic feature of bronchiolitis as it is in asthma, and thus hypertonic saline
theoretically should not induce such bronchospasm in patients with bronchiolitis without
concomitant asthma. There was a retrospective cohort study12 that looked at the adverse effect
profile of nebulized 3% hypertonic saline in 68 patients with acute bronchiolitis. A total of 377
doses were administered without a bronchodilator, with a resultant 1% adverse event rate. The
study notes that most adverse events were mild (being described as coughing), but one adverse
event was classified as bronchospasm. Due to these findings, subsequent studies evaluating
hypertonic saline’s efficacy in the setting of acute bronchiolitis utilize a bronchodilator with the
intervention to potentially mitigate the potential risk for bronchospasm. For that reason, the
studies were all limited because the bronchodilator therapy may have had an interacted with the
intervention such that the benefit of hypertonic saline was masked or interfered with.
Additionally, there is no way to discern the children with hyperreponsive bronchioles who will
eventually be diagnosed with asthma from those without. Hence, there is no current method to
identify how many of each future asthmatic was in each study group, which could affect
admission rate since the pathophysiology and treatment of asthma exacerbation is different than
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1
that of bronchiolitis. Lastly, the 7% nebulized hypertonic saline that Jacobs et al used could have
induced bronchospasm in that subset of patients with reactive airways.
Because emergency rooms are obligated by federal law to provide care to all patients
irrespective of their ability to pay, insurance coverage was not an issue in any of the studies.
Additionally, nebulized hypertonic saline is inexpensive and widely available in the United
States, making it easily obtainable for patients if need be. Therefore, insurance and access to the
study drug were non-issues and did not affect the results of the studies.
CONCLUSION
The trials analyzed in this EBM review showed conflicting evidence regarding nebulized
hypertonic saline solution’s capacity to reduce hospital admission in patients with bronchiolitis in
the emergency department. The study by Wu et al demonstrated the most convincing data that
such an intervention reduces admission rate, as well as was the largest study to date analyzing this
topic. Jacobs et al suggested nebulized hypertonic saline reduces admission rate with a smaller
study population, but the data was not statistically significant. Lastly, Florin et al found that
nebulized hypertonic saline actually produces worse outcomes when it regards hospitalization rate,
but again was not statistically significant.
Future study is warranted to definitively evaluate the efficacy of nebulized hypertonic
saline at reducing admission in the setting of acute bronchiolitis. Additionally, populations for
future studies should ideally be large and diversified to eliminate the argument that small study
population and narrow racial representation may have led to inaccurate results. Because the
American Academy of Pediatrics recommends against the use of bronchodilator therapy in the
management of acute bronchiolitis without concomitant respiratory disease, future study may
benefit from the use of nebulized hypertonic saline without such bronchodilator therapy.
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